This company has been acquired
Marinus Pharmaceuticals (MRNS) Stock Overview
A pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MRNS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Marinus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.55 |
| 52 Week High | US$10.50 |
| 52 Week Low | US$0.22 |
| Beta | 1.03 |
| 1 Month Change | 2.33% |
| 3 Month Change | 59.32% |
| 1 Year Change | -94.62% |
| 3 Year Change | -95.12% |
| 5 Year Change | -94.03% |
| Change since IPO | -98.28% |
Recent News & Updates
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price
It's not a stretch to say that Marinus Pharmaceuticals, Inc.'s ( NASDAQ:MRNS ) price-to-sales (or "P/S") ratio of 2.9x...Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest quarterly results, disappointing...Recent updates
Shareholder Returns
| MRNS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.0% | 0.9% |
| 1Y | -94.6% | 37.2% | 24.5% |
Return vs Industry: MRNS underperformed the US Pharmaceuticals industry which returned 1.2% over the past year.
Return vs Market: MRNS underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| MRNS volatility | |
|---|---|
| MRNS Average Weekly Movement | 16.3% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MRNS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MRNS's weekly volatility has decreased from 21% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 166 | Scott Braunstein | marinuspharma.com |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
Marinus Pharmaceuticals, Inc. Fundamentals Summary
| MRNS fundamental statistics | |
|---|---|
| Market cap | US$30.32m |
| Earnings (TTM) | -US$140.49m |
| Revenue (TTM) | US$31.47m |
Is MRNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNS income statement (TTM) | |
|---|---|
| Revenue | US$31.47m |
| Cost of Revenue | US$102.78m |
| Gross Profit | -US$71.31m |
| Other Expenses | US$69.18m |
| Earnings | -US$140.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.55 |
| Gross Margin | -226.64% |
| Net Profit Margin | -446.49% |
| Debt/Equity Ratio | -141.4% |
How did MRNS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/10 16:05 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marinus Pharmaceuticals, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kimberly Lee | Brean Capital Historical (Janney Montgomery) |
| François Brisebois | Craig-Hallum Capital Group LLC |
| Douglas Tsao | H.C. Wainwright & Co. |